Germ-line mutations of the BRCA2 gene cause inherited susceptibility to breast and ovarian cancers. BRCA2 contains two nuclear localization signals, predominantly localizes in the nucleus and plays significant roles in DNA double-strand break repair. Recently, we reported that BRCA2 localizes to the centrosomes during the S and early M phases of the cell cycle. In this study, for the first time, we identified a functional nuclear export sequence (NES1; 1383 DLSDLTFLEVA 1393 ) in BRCA2. The green fluorescent protein (GFP)-NES1 fusion protein was localized in the cytoplasm and could be blocked by the chromosomal region maintenance 1-specific export inhibitor leptomycin B. Mutation of a leucine residue in the NES1 motif to alanine (L1384A) resulted in both cytoplasmic and nuclear localization of the GFP-NES1 fusion protein and a nuclear accumulation of ectopic fulllength BRCA2-FLAG. Moreover, treatment of cells with leptomycin B decreased centrosomal localization of BRCA2. Finally, by microinjection of an anti-BRCA2 antibody into the cytoplasm of HeLa S3 cells, we found that depletion of normal BRCA2 proteins in the cytoplasm leads to centrosome amplification and binucleated cells. Our results suggest that disruption of the NES function by genetic changes results in deregulation of BRCA2 export, which ultimately leads to centrosome disorder.
Introduction
Inherited mutations in the breast cancer susceptibility gene BRCA2 predispose to breast and ovarian cancer, as well as other epithelial cancers (Wooster et al., 1995; Venkitaraman, 2002) . BRCA2 forms complexes with Rad51 and plays important roles in the maintenance of genomic stability during DNA recombination and double-strand break repair (Wong et al., 1997; Yang et al., 2005) . BRCA2-null murine embryonic fibroblasts exhibit centrosome amplification (Tutt et al., 1999) , spontaneous accumulation of chromosomal abnormalities (Tutt et al., 1999) and defective cytokinesis (Daniels et al., 2004) . Recently, we reported that BRCA2 localizes to the centrosomes during the S and early M phases of the cell cycle (Nakanishi et al., 2007) . The centrosomal localization of BRCA2 prompted us to investigate whether nuclear-cytoplasmic shuttling mechanisms are involved in regulating the subcellular distribution of BRCA2.
Nuclear localization signals (NLSs) have been identified at the C terminus of BRCA2, and wild-type BRCA2 is predominantly located within the nucleus (Yano et al., 2000) . In contrast, BRCA2 is cytoplasmically localized in the human pancreatic cell line, Capan 1, which has lost one BRCA2 allele and carries a 6174delT mutation in the remaining one; cytoplasmic localization was also observed for green fluorescent protein (GFP)-tagged BRCA2 deletion mutants (D1529-3418 and D2889-3418) (Spain et al., 1999) . The BRCA2 mutants D2723H and R2659K were also localized predominantly in the cytoplasm in >90% of transfected cells (Wu et al., 2005) . These mutations do not directly disrupt the known NLS motifs, suggesting that previously undetected sites might be mediating BRCA2 localization.
The control of subcellular protein localization by active nucleocytoplasmic transport mechanisms is essential for the regulation of protein function in various biological processes, such as cell proliferation, transformation and tumorigenesis (Weis, 2003) . The translocation of macromolecules larger than 60 kDa into and out of the nucleus is an active, energy-dependent process that is mediated by specific sequence motifs, NLSs and nuclear export signals (NESs) (Gorlich and Kutay, 1999; Bednenko et al., 2003) . In fact, several proteins involved in DNA repair pathways and maintenance of genome integrity, such as BRCA1 and p53, were recently shown to be regulated by shuttling between the nucleus and the cytoplasm (Zhang and Xiong, 2001; Thompson et al., 2005; ) . Their expulsion from the nucleus generally depends upon an NES, a short leucinerich motif that is specifically recognized by the nuclear export receptor known as chromosomal region maintenance 1 (CRM1; Fukuda et al., 1997) .
In this study, we show that a functional NES (   1383   DLSDLTFLEVA   1393 ) is present in the BRCA2 protein, and BRCA2 is able to exit the nucleus via the CRM1-dependent pathway. We also demonstrate that this NES is essential for the centrosomal localization of BRCA2.
Results

Prediction of a BRCA2 nuclear export signal
Although it is well known that endogenous BRCA2 is localized predominantly in the nucleus (Spain et al., 1999; Yano et al., 2000) , we have recently shown that BRCA2 also localizes to the centrosomes (Nakanishi et al., 2007) . This pattern of subcellular localization led us to test whether BRCA2 has a nuclear export activity. Therefore, we first searched for leucine-rich NES sequences in BRCA2 and identified two potential NES motifs (NES1;
1383
DLSDLTFLEVA
1393 and NES2; 3270 ALDFLSRLPLP 3280 ) ( Figure 1 ). We compared these sequences (NES1 and NES2) with the NESs of other proteins such as APC, p53 (Fabbro and Henderson, 2003) , c-Abl (Taagepera et al., 1998) and BRCA1 (Fabbro and Henderson, 2003; Thompson et al., 2005) by aligning them based on the consensus sequence. Additionally, we compared the BRCA2 NES sequences among a variety of species (chimpanzee, mouse and rat). These putative NES motifs are very well conserved (Figure 1 ).
The region between residues 1383 and 1393 (NES1) of BRCA2 is required for cytoplasmic localization To determine whether these NESs alone can direct nuclear export, plasmids were constructed which expressed the putative NES1 or NES2 fused to the C terminus of GFP (GFP-NES1 and GFP-NES2). HeLa cells were transfected with GFP-NES1, GFP-NES2 or GFP expression vector, and examined live by fluorescence microscopy. As shown in Figure 2 , most cells (75.5±0.68%) transfected with nonchimeric GFP showed an even distribution in the cytoplasm and the nucleus. In contrast, the majority (83.9 ± 5.51%) of cells expressing GFP-NES1 showed primarily cytoplasmic localization. Unexpectedly, GFP-NES2 was distributed in both the nucleus and the cytoplasm, like unmodified GFP (77.2±1.89%). Thus, the NES1, but not NES2, of BRCA2 is sufficient to direct the exclusion of the GFP fusion constructs from the nucleus. Similar results were obtained in COS7 cells (data not shown).
Leptomycin B (LMB; Calbiochem, CA, USA), a specific inhibitor of the nuclear export receptor CRM1, prevents the CRM1/NES interaction and thus induces the accumulation of shuttling proteins into the nucleus (Kudo et al., 1998) . To determine whether the nuclear export of GFP fused to NES1 and NES2 was CRM-1 dependent, we looked for LMB-induced changes in subcellular localization. Fluorescence microscopy demonstrated that a 3-h incubation with 5 nM LMB induced clear accumulation of GFP-NES1 and a very slight increase of GFP-NES2 in the nucleus (Figure 2a ). Since treatment with LMB resulted in an increase of GFP-NES1 within the nucleus (N>C bar), this indicates that LMB blocked the export of GFP-NES1. LMB also increased GFP-NES2 accumulation in the nucleus (N>C bar), suggesting that NES2 may still have some effect on nuclear export activity, although this may not be as dominant as that of NES1. Also, the subcellular localization of GFP was not affected by LMB treatment (Figure 2b ; Po0.05 for GFP-NES1 and GFP-NES2 versus GFP treated with LMB). These observations suggested that the subcellular localization of GFP-NES1 and GFP-NES2 may be regulated by CRM1. The NES consensus as it appears from sequence comparisons clearly reveals that the conserved aminoacid pattern includes not just large hydrophobic residues but also negatively charged ones. Using two-dimensional gel electrophoresis of glutathione S-transferase (GST) fusion proteins, we observed that NES1 and NES2, which differ in their effect on subcellular localization, show a concomitant difference in their pIs (Supplementary Figure S1) . The greater acidity of NES1 is consistent with the lower pI predicted for the NES1 peptide using GENETYX-WIN (2.9 for NES1 versus Figure 1 Comparison of putative nuclear export sequences (NESs) in BRCA2 protein with other well-characterized NES motifs and BRCA2 homologs of various species. NESs identified in APC, p53 and BRCA1, as well as two putative NESs (NES1 and NES2) in the BRCA2 protein, are shown. These putative BRCA2 NES sequences are well conserved in various species. The aminoacid numbers are based on amino-acid sequences from accession numbers NM 000059 (Homo sapiens), XM 509619 (chimpanzee), U65594 (mouse) and NM 031542 (rat) in GenBank. In the consensus NES sequence, Ø indicates a large hydrophobic residue, such as leucine, isoleucine, valine or methionine, and X indicates any amino acid. Residues critical to NES activity are indicated by red letters.
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X Han et al 6.9 for NES2). For the above-mentioned reason, we focused on NES1. The pI calculation, using GENE-TYX-WIN was made for the NES only.
Mutational analysis of the NES1
To investigate the dependence of nuclear export activity on amino-acid sequence in NES1, point mutations within NES1 in which one or two leucine residues were replaced with alanine (L1384A; NES1m1, L1384A and L1387A; NES1m2) were generated ( Figure 3a ). The NES1, NES1m1 and NES1m2 peptides were fused to GFP, and as shown in Figure 3b , NES1m1 and NES1m2, unlike wild-type NES1, were incapable of directing GFP to the cytoplasm. The subcellular localization of GFP-NES1m1 and GFP-NES1m2 was not substantially affected by LMB treatment (Figure 3b ), thus demonstrating that the NES1 is sufficient to direct GFP to the cytoplasm. These results, which were further supported by immunofluorescence experiments (Supplementary Figure S2) , provide clear evidence that hydrophobic residues are also crucial for the activity of the NES.
Mutation of the NES1 (L1384A) leads to enhanced nuclear accumulation of full-length BRCA2
To assess the role of the NES in exporting full-length BRCA2, we determined the effect of mutating this export sequence on BRCA2 localization. We used sitedirected mutagenesis to generate an NES-defective version of BRCA2 (BRCA2m1) in which leucine 1384 was mutated to alanine. As a control, wild-type BRCA2-FLAG and BRCA2L3271A-FLAG, in which alanine was substituted for leucine at codon 3271, were prepared. COS7 cells were transfected with wild-type BRCA2-FLAG, BRCA2m1-FLAG or BRCA2m2-FLAG, and 24 h after transfection, indirect immunostaining of FLAG was used to detect the proteins. In 72 ± 9.6% of cells expressing wild-type BRCA2, the Nuclear export signal in BRCA2 X Han et al FLAG-tagged protein was predominantly nuclear, although some cytoplasmic staining was detectable (Figure 4 ). In contrast, 67 ± 3.2% of cells expressing FLAG-BRCA2m1 showed complete nuclear localization. But, as seen in Figure 4 , the L3271A mutant protein localized similarly to wild-type BRCA2 and was predominantly nuclear with detectable cytoplasmic staining. Western blot analysis of the nuclear and cytoplasmic fractions of COS-7 cells, transfected with wild-type BRCA2-FLAG and BRCA2m1-FLAG, further supported the results observed by fluorescence microscopy (Supplementary Figure S3) . Collectively, these results demonstrate that the NES1 reported here mediates BRCA2 nuclear export.
Centrosomal localization of BRCA2 is sensitive to LMB Endogenous BRCA2 was observed in the nucleus and centrosomes (Nakanishi et al., 2007) by immunofluorescence analysis. This observation suggests that a At least 100 cells from each transfection were scored as predominantly nuclear (N>C), nuclear and cytoplasmic (N ¼ C) or predominantly cytoplasmic (NoC), respectively.
Nuclear export signal in BRCA2 X Han et al portion of the BRCA2 in the nucleus might be shifted to the centrosomes. To test this possibility, we examined the influence of LMB on centrosomal localization of endogenous BRCA2 in HeLa cells that were during the S phase and early M phase of the cell cycle (Figure 5a ). Cells were treated with or without 5 nM LMB for 5 h, and subjected to immunofluorescence microscopy using antibodies against BRCA2 (H-299) and g-tubulin (C-11). In untreated cells (n ¼ 35), BRCA2 was localized to the nuclear and centrosomal regions (100%). In contrast, among LMB-treated cells (n ¼ 40), 32.5±12.0% lacked BRCA2 immunofluorescence in and around the centrosomes (Figure 5 ; Po0.05 for LMB-treated versus -untreated HeLa cells, MannWhitney U-test, two-tailed). These results indicate that the NES1 motif contributes to centrosomal localization of BRCA2.
Depletion of normal BRCA2 proteins in the cytoplasm leads to centrosome amplification and binucleated cells To examine the functional role of BRCA2 in cellular cytoplasm, we examined how microinjecting anti-BRCA2 antibody (Ab-1) into the cytoplasm of HeLa S3 cells affected the centrosomes. Normal mouse immunoglobulin G (IgG) was used as a control. After culturing the injected cells for 24 h, cells were examined by immunostaining for a-and g-tubulin (Figure 6a ). The percentage of cells with multiple (three or more) centrosomes in the anti-BRCA2 antibody-injected cells was significantly increased (Po0.05, 30.7±8.9 versus 11.6±2.9% in control cells) (Figure 6b) . Furthermore, the percentage of cells harboring two nuclei in the anti-BRCA2 antibody-injected cells was significantly increased (Po0.05, 61.3±3.2 versus 7.2±3.5% in control cells) (Figure 6b ). These results strongly suggest that the absence of BRCA2 Figure 4 Point mutation in NES1 induces nuclear accumulation of full-length BRCA2. (a) HeLa cells were transfected with constructs encoding full-length FLAG-tagged wild-type BRCA2 (BRCA2-FLAG), BRCA2 with leucine 1384 mutated to alanine (BRCA2L1384A-FLAG) and BRCA2 with leucine 3271 mutated to an alanine (BRCA2L3271A-FLAG). After 24 h, indirect immunostaining was performed using an anti-FLAG antibody (green) to determine subcellular localization of wild-type and mutated BRCA2-FLAG. Nuclei were detected with Hoechst 33258 (blue). (b) Graphs show the results (mean±s.d.) of at least three experiments in which the proportion of transfected cells displaying predominantly nuclear with cytoplasm (N þ C) or completely nuclear (N) localization of BRCA2 was scored. More than 50 transfected cells were counted per experiment. Scale bar, 5 mm.
predisposes the cells to cytokinesis failure, thereby increasing the number of binucleated cells, and consequently increasing the centrosome number per cell. Also, the possibility of a direct effect of BRCA2 absence on centrosome amplification cannot be excluded.
Discussion
We have demonstrated that BRCA2 possesses a functional NES that is necessary for cytoplasmic retention. Our conclusion is based on three observations. First, the sequence between amino acids 1383 and 1393 (NES1) closely fit the consensus pattern of hydrophobic residue characteristics of NESs. Second, this sequence was able to mediate nuclear export of a GFP fusion protein and the export was inhibited by treatment with LMB. Third, point mutation of the critical leucine in the core region of this sequence abrogated export of GFP-NES1 and BRCA2-FLAG proteins. Our findings suggest that BRCA2 is subject to active nuclear export.
The BRCA2 has two NLS elements in the C terminus that direct its movement into the nucleus. However, a mechanism for nuclear export of BRCA2 has not been previously reported. The lack of data describing nuclearcytoplasmic shuttling of BRCA2 may be because BRCA2 is usually found to occur in the nucleus of cells, and a cytoplasmic distribution of BRCA2 has only been attributed to the expression of a truncated protein that has lost the C-terminal NLS (Spain et al., 1999) . This has been observed in transiently expressed proteins. Experiments with BRCA2-GFP fusion proteins have demonstrated that even truncating 155 residues from the C terminus of BRCA2 completely abrogates its nuclear localization. However, although BRCA2 appears predominantly nuclear, it may still shuttle between nucleus and cytoplasm, if the rate of nuclear import is greater than the rate of nuclear export. Specific conditions may shift the steady-state kinetics toward nuclear export. Many conditions, including changes in the cell cycle, have been reported to alter the shuttling of proteins between nucleus and cytoplasm. For example, phosphorylation has been shown to be important in regulating the subcellular localization of many proteins such as nucleophosmin (Wang et al., 2005) and p53 (Zhang and Xiong, 2001 ). Cyclin-dependent kinases (CDK) have been shown to phosphorylate BRCA2 on serine 3291 near the NLS (Esashi et al., 2005) , blocking C-terminal interactions with RAD51. CDK may be a logical candidate for a regulator of BRCA2 trafficking.
The shuttling of BRCA2 between nucleus and cytoplasm may have biological significance. In support of this notion, we recently showed that BRCA2 localizes to the centrosome during the S and early M phases (Nakanishi et al., 2007) . BRCA2 has a centrosomal localization signal (CLS) that is essential for centrosomal targeting. GFP fused to the CLS peptides from BRCA2 localizes to centrosomes and prevents endogenous BRCA2 from localizing to the centrosomes (Nakanishi et al., 2007) . However, it was unclear whether BRCA2 localizes to the centrosomes directly after being synthesized in the cytoplasm, or is first transported into the nucleus and is then exported out again into the cytoplasm where it can then localize to the centrosomes. To distinguish between these possibilities, we performed immunofluorescence microscopy using anti-BRCA2 antibody on HeLa cells treated with or without LMB. We observed that centrosomal immunofluorescence was decreased in the LMB-treated cells (Figure 5 ), suggesting that BRCA2 is not directly translocated to the centrosomes from the cytoplasm Figure 5 Leptomycin B (LMB) prevents endogenous BRCA2 from localizing to the centrosome. (a) HeLa cells with or without LMB treatment for 6 h were subjected to immunofluorescence analysis with anti-BRCA2 (Ab-2; green) and anti-g-tubulin antibody (C-11; red). Nuclei were detected with Hoechst 33258 (blue). The magnified area represents the region of the main image around the centrosome denoted by the arrowheads. Scale bar, 5 mm. (b) In untreated cells (n ¼ 35) at the S phase or early M phase, BRCA2 was localized to the nuclear and centrosomes (100%). In contrast, BRCA2 was localized to the centrosomes in 67.5 ± 12.0% of LMBtreated cells (n ¼ 40). Graphs show the results (mean ± s.d.) of at least three experiments in which the proportion of HeLa cells with or without LMB treatment showing centrosomal localization of BRCA2 was scored.
Nuclear export signal in BRCA2 X Han et al after protein synthesis, but rather exists in the nucleus before being translocated to the centrosomes (Figure 7b) . Furthermore, mutation of the NES enhanced BRCA2 nuclear localization (Figures 4 and  7c) . We provide evidence that BRCA2 undergoes nucleocytoplasmic shuttling. Thus, these results suggest Nuclear export signal in BRCA2 X Han et al that BRCA2 can be translocated to the nucleus from cytoplasm by the activity of NLS, then moves to the cytoplasm by the activity of the NES and is finally translocated to the centrosomes by the activity of a CLS (Figure 7a ). In this study, we found potential NES sequences (amino acids 1383-1393) in BRCA2. According to the Breast Cancer Information Core (BIC), which was established in the National Human Genome Research Institute to coordinate the information related to BRCA1 and BRCA2 research, 14 examples of mutations in this sequence have been reported as unverified changes. We demonstrated in this study that depletion of normal BRCA2 proteins in the cytoplasm leads to centrosome amplification and binucleated cells, suggesting that disruption of the NES function by genetic changes results in deregulation of BRCA2 export, which then leads to centrosome amplification and binucleated cells. Although the cellular role of the 14 examples of mutations in this sequence, reported in BIC, remains to be confirmed, it is conceivable that these alterations may deregulate BRCA2 export and thereby contribute to breast tumorigenesis.
Materials and methods
Cell cultures, transfection and leptomycin B treatment HeLa S3 cells (RIKEN Gene Bank) and COS7 cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. Transfection was performed using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. When required, LMB was added at a final concentration of 5 nM for the indicated time.
Plasmid constructs
Wild-type GFP-NES1 and GFP-NES2, mutant GFP-NES1m1 and GFP-NES1m2 constructs were created by annealing double-stranded oligonucleotides into the expression vector, pEGFP-C1 (Clontech, Palo Alto, CA, USA). For the construction of wild-type GFP-NES1, the oligonucleotides 5 0 -GATCTCGAGCTGATTT-GTCAGATTTAACTTTTTTG GAAGTTGCGTGAATTCTGC-3' and 5 0 -GCAGAATTCAC GCAACTTCCAAAAAAGTTAAATCTGACAAATCAGCT CGAGATC-3 0 were annealed and ligated into pEGFP-C1. For the construction of mutant GFP-NES1m1, the oligonucleotides 5 0 -GATCTCGAGCTGATGCATCAGATGCAACTTTTTTG GAAGTTGC-GTGAATTCTGC-3 0 and 5 0 -GCAGAATTC ACGCAACTTCCAAAAAAGTTGCATCTGAT-GCATCA GCTCGAGATC-3 0 were used. For construction of mutant GFP-NES1m2, the oligonucleotides 5 0 -GATCTCGAGCTGA TGCATCAGATTTAACTTTTTTGGAAGTTGC-GTGAA TTCTGC-3 0 and 5 0 -GCAGAATTCACGCAACTTCCAAAA AAGTTAAATCTGAT-GCATCAGCTCGAGATC-3 0 were used. For construction of GFP-NES2, the oligonucleotides 5 0 -GATCTCGAGCTGCCTTGGATTTCTTGAGTAGACT GCCTTTACC-TTGAATTCTGC-3 0 and 5 0 -GCAGAATT CAAGGTAAAGGCAGTCTACTCAAGAAATCC-AAGG CAGCTCGAGATC-3 0 were used. GST-NES1 and GST-NES2 constructs were created by annealing double-stranded oligonucleotides as identified above into the expression vector, pGEX4T-2 plasmid (Amersham Biosciences, Buckinghamshire, UK), respectively. Construction of the wild-type BRCA2-FLAG expression plasmid (pME18sBRCA2-FLAG) has been described previously (Nakanishi et al., 2007) . Full-length human BRCA2 cDNA, a gift from FJ Couch (Mayo Clinic and Foundation), was subcloned into the pME18S-FL3 plasmid. The L1384A and L3271A mutations of BRCA2 were created directly in the pME18sBRCA2-FLAG construct using a Quikchange XL site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA). The forward primers were 5 0 -CAGATT AAAGAA-GATGCGTCAGATTTAACTTTTTTG-3 0 (L1384A) and 5 0 -GCAAAAAGAGAAGAGCCG-CGGATTTCTTGA GTAGAC-3 0 (L3271A), and the reverse primers were 5 0 -CA AAAAAGTTAAATCTGACGCATCTTCTTTAATCTG-3 0 (L1384A) and 5 0 -GTCTACT-CAAGAAATCCGCGGCTCT CTTTTTGC-3 0 (L3271A). All the plasmids were verified by DNA sequencing.
Immunofluorescence and green fluorescence microscopy Cell fixation and immunostaining were performed as described previously (Nakanishi et al., 2007) . FLAG-tagged BRCA2 was detected directly following fixation, washing and mounting. Anti-FLAG (F3165), anti-BRCA2 (Ab-2) and anti-g-tubulin (C-11) antibody were used at 1:1000, 1:100 and 1:1000 dilutions, respectively, in the blocking solution. The cells were then incubated with Alexa Fluor 488-or 594-conjugated secondary antibody (Molecular Probes, Eugene, OR, USA) diluted 1:200 in blocking solution. DNA was stained with Hoechst 33258, and coverslips were mounted on slides with ProLong Gold (Invitrogen). Cells were examined with an Olympus Power BX51 fluorescence microscope (Olympus Co., Tokyo, Japan). GFP fluorescence was analysed in living cells with a Leica DMI 6000B microscope and photographed at a magnification of Â 640.
Microinjection
Using a CI-2000 automated cell injector system (Fujitsu, Japan) and inverted microscope, BRCA2 antibody at a concentration of 0.05 mg ml
À1
, together with Alexa 594 (Molecular Probes), was injected into HeLa S3 cells cultured on glass coverslips with grid markings (Matrunami glass, Japan). Control injections were performed using normal mouse IgG (Sigma-Aldrich, St Louis, MO, USA) at the same concentration. Prior to immunostaining with a-and g-tubulin antibody, Alexa 594 was observed by means of a fluorescent microscope, to determine which cells had been injected on the grid marking the glass coverslip. At 24 h after injection, the coverslips were fixed and processed for immunofluorescence as described above.
